Biodexa Pharmaceuticals PLC

Contributing Author

Recent Articles by Biodexa Pharmaceuticals PLC

Aug-18	Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jul-31	ADR Ratio Change Effective BDRX GlobeNewswire
Jul-15	ADR Ratio Change BDRX GlobeNewswire
Jul-14	Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jun-27	Results of Annual General Meeting BDRX GlobeNewswire
Jun-25	Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jun-23	Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) BDRX GlobeNewswire
Jun-11	Result of General Meeting BDRX GlobeNewswire
Jun-04	Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes BDRX GlobeNewswire
May-30	Shareholder Update BDRX GlobeNewswire
May-22	Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Notice of General Meeting BDRX GlobeNewswire
May-22	Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M BDRX GlobeNewswire
May-12	Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP BDRX GlobeNewswire
May-02	Result of General Meeting BDRX GlobeNewswire